Cargando…
The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder clinically defined by cytopenias, bone marrow failure, and an increased risk of progressing to acute myeloid leukemia (AML). Traditionally, first-line treatment for patients with higher-risk MDS has been hypomethylating agen...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310330/ https://www.ncbi.nlm.nih.gov/pubmed/35898435 http://dx.doi.org/10.1177/20406207221112899 |
_version_ | 1784753362365841408 |
---|---|
author | Snow, Anson Zeidner, Joshua F. |
author_facet | Snow, Anson Zeidner, Joshua F. |
author_sort | Snow, Anson |
collection | PubMed |
description | Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder clinically defined by cytopenias, bone marrow failure, and an increased risk of progressing to acute myeloid leukemia (AML). Traditionally, first-line treatment for patients with higher-risk MDS has been hypomethylating agents (HMAs). However, these agents have modest clinical activity as single agents. A one-size-fits-all treatment paradigm is insufficient for such a heterogeneous disease in the modern era of precision medicine. Several new agents have been developed for MDS with the hopes of improving clinical outcomes and survival. Pevonedistat is a first-in-class, novel inhibitor of neuronal precursor cell-expressed developmentally down-regulated protein-8 (NEDD8) activating enzyme (NAE) blocking the neddylation pathway leading to downstream effects on the ubiquitin–proteosome pathway. Pevonedistat ultimately leads to apoptosis and inhibition of the cell cycle in cancer cells. Studies have demonstrated the safety profile of pevonedistat, leading to the development of multiple trials investigating combination strategies with pevonedistat in MDS and AML. In this review, we summarize the preclinical and clinical rationale for pevonedistat in MDS and AML, review the clinical data of this agent alone and in combination with HMAs to date, and highlight potential future directions for this agent in myeloid malignancies. |
format | Online Article Text |
id | pubmed-9310330 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-93103302022-07-26 The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype? Snow, Anson Zeidner, Joshua F. Ther Adv Hematol Review Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder clinically defined by cytopenias, bone marrow failure, and an increased risk of progressing to acute myeloid leukemia (AML). Traditionally, first-line treatment for patients with higher-risk MDS has been hypomethylating agents (HMAs). However, these agents have modest clinical activity as single agents. A one-size-fits-all treatment paradigm is insufficient for such a heterogeneous disease in the modern era of precision medicine. Several new agents have been developed for MDS with the hopes of improving clinical outcomes and survival. Pevonedistat is a first-in-class, novel inhibitor of neuronal precursor cell-expressed developmentally down-regulated protein-8 (NEDD8) activating enzyme (NAE) blocking the neddylation pathway leading to downstream effects on the ubiquitin–proteosome pathway. Pevonedistat ultimately leads to apoptosis and inhibition of the cell cycle in cancer cells. Studies have demonstrated the safety profile of pevonedistat, leading to the development of multiple trials investigating combination strategies with pevonedistat in MDS and AML. In this review, we summarize the preclinical and clinical rationale for pevonedistat in MDS and AML, review the clinical data of this agent alone and in combination with HMAs to date, and highlight potential future directions for this agent in myeloid malignancies. SAGE Publications 2022-07-22 /pmc/articles/PMC9310330/ /pubmed/35898435 http://dx.doi.org/10.1177/20406207221112899 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Snow, Anson Zeidner, Joshua F. The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype? |
title | The development of pevonedistat in myelodysplastic syndrome (MDS) and
acute myeloid leukemia (AML): hope or hype? |
title_full | The development of pevonedistat in myelodysplastic syndrome (MDS) and
acute myeloid leukemia (AML): hope or hype? |
title_fullStr | The development of pevonedistat in myelodysplastic syndrome (MDS) and
acute myeloid leukemia (AML): hope or hype? |
title_full_unstemmed | The development of pevonedistat in myelodysplastic syndrome (MDS) and
acute myeloid leukemia (AML): hope or hype? |
title_short | The development of pevonedistat in myelodysplastic syndrome (MDS) and
acute myeloid leukemia (AML): hope or hype? |
title_sort | development of pevonedistat in myelodysplastic syndrome (mds) and
acute myeloid leukemia (aml): hope or hype? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310330/ https://www.ncbi.nlm.nih.gov/pubmed/35898435 http://dx.doi.org/10.1177/20406207221112899 |
work_keys_str_mv | AT snowanson thedevelopmentofpevonedistatinmyelodysplasticsyndromemdsandacutemyeloidleukemiaamlhopeorhype AT zeidnerjoshuaf thedevelopmentofpevonedistatinmyelodysplasticsyndromemdsandacutemyeloidleukemiaamlhopeorhype AT snowanson developmentofpevonedistatinmyelodysplasticsyndromemdsandacutemyeloidleukemiaamlhopeorhype AT zeidnerjoshuaf developmentofpevonedistatinmyelodysplasticsyndromemdsandacutemyeloidleukemiaamlhopeorhype |